Antipsychotic Use in Dementia: CMS Expectations and Alternatives
A consultant pharmacist's guide to antipsychotic use in dementia in the nursing home: CMS expectations, GDR principles, and evidence-informed alternatives.
This post is for consultant pharmacists, SNF (skilled nursing facility) Directors of Nursing, and compliance officers who own the hard conversations about antipsychotic use in dementia nursing home populations. You will get a practical framing of what CMS (Centers for Medicare & Medicaid Services) expects, how the medication regimen review (MRR) connects to those expectations, and the non-drug and clinical alternatives that belong in the record before a prescription does.
Why antipsychotic use in dementia stays under scrutiny
Antipsychotics are frequently used to manage behavioral and psychological symptoms of dementia (BPSD), yet the evidence for benefit in that setting is limited and the safety concerns are serious. The FDA has issued boxed warnings describing increased mortality when antipsychotics are used to treat dementia-related psychosis in older adults. That tension — real distress in the resident, limited benefit, documented risk — is why this drug class draws persistent regulatory and clinical attention.
The American Geriatrics Society (AGS) Beers Criteria flag antipsychotics as potentially inappropriate in older adults in several circumstances, including use for BPSD absent specific conditions. STOPP/START (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) similarly scrutinizes antipsychotics in frail older patients. Both tools are periodically updated, so confirm the current criteria against the published source rather than memory.
What CMS expects in the SNF setting
CMS has run a long-standing national effort to reduce unnecessary antipsychotic use in nursing homes, and surveyors evaluate unnecessary-drug and psychotropic-medication requirements under the State Operations Manual and the associated F-tags. Rather than citing a specific tag number here, work from the current CMS guidance and your facility's compliance team, because interpretive guidance is updated over time. You can review the authoritative requirements directly at cms.gov.
In practical terms, CMS expectations converge on a few documented behaviors:
- Indication and diagnosis. The record should support why an antipsychotic is used, not merely that a behavior occurred.
- Non-pharmacologic approaches first. Attempted and documented interventions before, or alongside, any medication.
- Informed consent and monitoring. Evidence that risks were discussed and that the resident is monitored for efficacy and adverse effects.
- Gradual dose reduction (GDR). A documented plan to attempt dose reduction unless clinically contraindicated, with the clinical rationale captured when a GDR is deferred.
The consultant pharmacist is central to each of these. Your MRR is where the clinical case for continuing, reducing, or discontinuing is evaluated and recorded with professional judgment.
WeConsultRx gives you the WeConsultRx clinical engine — 49 codified rules across Beers 2023, STOPP/START v2, and ACB.
Gradual dose reduction as a clinical discipline, not a checkbox
GDR is often treated as a scheduling exercise. Treat it instead as a structured clinical question: is this medication still delivering benefit that outweighs its risk for this resident, and can the dose be lowered or stopped?
A defensible GDR workflow generally includes:
- Confirming the documented indication and whether it still applies.
- Reviewing behavioral trends and any objective monitoring since the last review.
- Evaluating whether a reduction attempt is appropriate or whether deferral is clinically justified.
- Recording the rationale either way, so the record stands on its own to a surveyor months later.
The consultant pharmacist evaluates whether a reduction is appropriate for an individual resident; this is a judgment made with the prescriber and care team, not a fixed rule applied to everyone. The value is in the documented reasoning, not merely the outcome.
Evidence-informed alternatives to reach for first
Most BPSD has triggers. Before reaching for a psychotropic, the care team investigates and addresses what is driving the behavior. Non-pharmacologic and clinical alternatives commonly considered include:
- Unmet-needs assessment. Pain, hunger, constipation, infection, hearing or vision loss, and sleep disruption are frequent, reversible drivers of agitation.
- Environmental and routine adjustments. Consistent caregivers, reduced noise, structured activity, daylight exposure, and familiar objects.
- Delirium screening. Acute behavior change warrants a delirium workup rather than a reflexive psychotropic.
- Deprescribing the contributors. Review the full regimen for medications that may worsen confusion or agitation, including those with high anticholinergic burden (ACB), which is independently associated with cognitive harm in older adults.
This is where antipsychotic review and broader geriatric deprescribing connect. A resident flagged for antipsychotic scrutiny often carries other potentially inappropriate medications; a single comprehensive review of Beers 2023, STOPP/START v2, and anticholinergic burden surfaces more than any one class examined in isolation. For how that review fits into a SNF program, see our SNF solution.
Building a record that survives survey
The weakest antipsychotic records are not the ones where the drug was used — they are the ones where the reasoning is missing. A defensible chart typically shows a clear indication, documented non-drug attempts, consent and monitoring, and a GDR history with explicit rationale for each decision.
Standardizing that documentation across a facility or a portfolio is where consultant pharmacists spend avoidable hours. Pulling the right criteria, writing the recommendation, routing it for prescriber response, and bundling the evidence for the next survey is repetitive work that benefits from a consistent workflow. You can see how that end-to-end review and report flow works on our features overview and across the broader platform.
A note on criteria currency
Beers, STOPP/START, and CMS interpretive guidance all change. Anchor your program to the published source of each: the AGS for Beers, the STOPP/START authors for that tool, and CMS for regulatory expectations. Treat any internal cheat sheet as a convenience, not the authority, and refresh it when the source updates.
How WeConsultRx helps
WeConsultRx runs your medication regimen review against a clinical engine of 49 codified rules spanning Beers 2023, STOPP/START v2, and anticholinergic burden, so antipsychotic concerns surface alongside the other potentially inappropriate medications in the regimen — not in isolation. The consultant pharmacist keeps full clinical judgment and sign-off; the platform delivers the flagged findings, drafts the recommendation, captures GDR rationale, and bundles an audit-ready report. Explore the clinical engine or request a demo to see it against your own review workflow.
Frequently asked questions
Are antipsychotics ever appropriate for dementia-related behaviors?
They can be, in specific clinical circumstances, but the evidence for benefit in dementia-related symptoms is limited and the FDA has issued boxed warnings on increased mortality in older adults with dementia-related psychosis. The decision is a clinical judgment made by the prescriber and care team with a documented indication, attempted alternatives, consent, and monitoring. This article is general education and not patient-specific medical advice.
What does CMS expect for antipsychotic use in nursing homes?
CMS evaluates psychotropic and unnecessary-drug requirements through its survey guidance, with expectations centered on a documented indication, non-pharmacologic approaches, informed consent, monitoring, and a gradual dose reduction plan unless clinically contraindicated. Because interpretive guidance and F-tags are updated over time, confirm current requirements at cms.gov and with your compliance team.
What is a gradual dose reduction (GDR)?
GDR is a documented attempt to lower or discontinue a psychotropic medication to the lowest effective dose, or to stop it, when clinically appropriate. When a reduction is deferred, the clinical rationale should be recorded so the decision is defensible on later review. The consultant pharmacist evaluates whether a reduction is appropriate for the individual resident.
How do Beers and STOPP/START apply to antipsychotics?
Both tools flag antipsychotics as potentially inappropriate for older adults in several circumstances, including use for behavioral symptoms of dementia absent specific conditions. Both are periodically updated, so verify entries against the current published criteria rather than a static internal list.